The post FDA approves new Covid vaccines with limits under RFK Jr. appeared on BitcoinEthereumNews.com. Pfizer’s Covid vaccine Comirnaty, seen at a CVS Pharmacy in Eagle Rock, California, Sept. 14, 2023. Irfan Khan | Los Angeles Times | Getty Images The Food and Drug Administration on Wednesday approved the latest round of Covid vaccines in the U.S., but set new limits on who can get them. The agency ended its broader authorization of the shots, only clearing them for people at higher risk of severe illness. That includes those 65 and up and younger adults with at least one underlying condition that puts them at higher risk. The move could complicate access to the shots for millions of Americans, and raises questions about whether insurance plans will still cover them for healthy adults. “The emergency use authorizations for Covid vaccines, once used to justify broad mandates on the general public during the Biden administration, are now rescinded,” Health and Human Services Secretary Robert F. Kennedy Jr. said in a post on X. “The American people demanded science, safety, and common sense,” he said. “This framework delivers all three.” It follows several efforts by Kennedy, a prominent vaccine skeptic, to change and undermine immunizations in the U.S. The new limited authorizations are a break from U.S. vaccine policy in previous years, which recommended an annual Covid shot for all Americans 6 months and up. A key panel of vaccine advisors to the Centers for Disease Control and Prevention must vote to recommend the Covid shots. But Kennedy earlier this year gutted that panel and named new members, some of whom are widely known vaccine critics. In the post, Kennedy said the shots are available for all patients who choose them after consulting with their doctors. But it’s unclear how easily patients without high risk factors will be able to get a Covid vaccine. Kennedy said the… The post FDA approves new Covid vaccines with limits under RFK Jr. appeared on BitcoinEthereumNews.com. Pfizer’s Covid vaccine Comirnaty, seen at a CVS Pharmacy in Eagle Rock, California, Sept. 14, 2023. Irfan Khan | Los Angeles Times | Getty Images The Food and Drug Administration on Wednesday approved the latest round of Covid vaccines in the U.S., but set new limits on who can get them. The agency ended its broader authorization of the shots, only clearing them for people at higher risk of severe illness. That includes those 65 and up and younger adults with at least one underlying condition that puts them at higher risk. The move could complicate access to the shots for millions of Americans, and raises questions about whether insurance plans will still cover them for healthy adults. “The emergency use authorizations for Covid vaccines, once used to justify broad mandates on the general public during the Biden administration, are now rescinded,” Health and Human Services Secretary Robert F. Kennedy Jr. said in a post on X. “The American people demanded science, safety, and common sense,” he said. “This framework delivers all three.” It follows several efforts by Kennedy, a prominent vaccine skeptic, to change and undermine immunizations in the U.S. The new limited authorizations are a break from U.S. vaccine policy in previous years, which recommended an annual Covid shot for all Americans 6 months and up. A key panel of vaccine advisors to the Centers for Disease Control and Prevention must vote to recommend the Covid shots. But Kennedy earlier this year gutted that panel and named new members, some of whom are widely known vaccine critics. In the post, Kennedy said the shots are available for all patients who choose them after consulting with their doctors. But it’s unclear how easily patients without high risk factors will be able to get a Covid vaccine. Kennedy said the…

FDA approves new Covid vaccines with limits under RFK Jr.

Pfizer’s Covid vaccine Comirnaty, seen at a CVS Pharmacy in Eagle Rock, California, Sept. 14, 2023.

Irfan Khan | Los Angeles Times | Getty Images

The Food and Drug Administration on Wednesday approved the latest round of Covid vaccines in the U.S., but set new limits on who can get them.

The agency ended its broader authorization of the shots, only clearing them for people at higher risk of severe illness. That includes those 65 and up and younger adults with at least one underlying condition that puts them at higher risk.

The move could complicate access to the shots for millions of Americans, and raises questions about whether insurance plans will still cover them for healthy adults.

“The emergency use authorizations for Covid vaccines, once used to justify broad mandates on the general public during the Biden administration, are now rescinded,” Health and Human Services Secretary Robert F. Kennedy Jr. said in a post on X.

“The American people demanded science, safety, and common sense,” he said. “This framework delivers all three.”

It follows several efforts by Kennedy, a prominent vaccine skeptic, to change and undermine immunizations in the U.S. The new limited authorizations are a break from U.S. vaccine policy in previous years, which recommended an annual Covid shot for all Americans 6 months and up.

A key panel of vaccine advisors to the Centers for Disease Control and Prevention must vote to recommend the Covid shots. But Kennedy earlier this year gutted that panel and named new members, some of whom are widely known vaccine critics.

In the post, Kennedy said the shots are available for all patients who choose them after consulting with their doctors. But it’s unclear how easily patients without high risk factors will be able to get a Covid vaccine.

Kennedy said the FDA has authorized Moderna‘s shot for those 6 months and up, Pfizer‘s vaccine for people ages five and up and Novavax‘s jab for those ages 12 and up, but for those specifically at higher risk of getting severely sick from the virus.

Adults ages 65 and up are at higher risk of severe Covid, and so are younger adults who are immunocompromised or have underlying medication conditions such as cancer, obesity, diabetes, chronic kidney disease and heart diseases, according to the CDC’s website.

In a release, Pfizer confirmed that the FDA had cleared its updated Covid shot for use in adults 65 and above and those ages five through 64 with at least one underlying condition that puts them at high risk for severe illness. The company will begin shipping the shot immediately, and it will be available in pharmacies, hospitals and clinics nationwide “in the coming days.”

In a separate release, Moderna also confirmed that its updated Covid shot is approved for those 65 and up and people 6 months through 64 years of age who are at higher risk of severe illness. The company added that its new, next-generation Covid vaccine is approved for older adults and high-risk patients ages 12 through 64. Moderna said it expects the shots to be available in the coming days.

Shares of Pfizer and Moderna were trading slightly higher Wednesday afternoon, while Novavax shares dipped.

This is breaking news. Please refresh for updates.

Source: https://www.cnbc.com/2025/08/27/fda-covid-vaccine-authorization–rfk.html

Market Opportunity
SynFutures Logo
SynFutures Price(F)
$0.006883
$0.006883$0.006883
-0.56%
USD
SynFutures (F) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact [email protected] for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Lucid to begin full Saudi manufacturing in 2026

Lucid to begin full Saudi manufacturing in 2026

Lucid Group, the US carmaker backed by the Public Investment Fund (PIF), reportedly plans to start full-scale vehicle manufacturing in Saudi Arabia this year, transitioning
Share
Agbi2026/01/15 15:52
Exploring Market Buzz: Unique Opportunities in Cryptocurrencies

Exploring Market Buzz: Unique Opportunities in Cryptocurrencies

In the ever-evolving world of cryptocurrencies, recent developments have sparked significant interest. A closer look at pricing forecasts for Cardano (ADA) and rumors surrounding a Solana (SOL) ETF, coupled with the emergence of a promising new entrant, Layer Brett, reveals a complex market dynamic. Cardano's Prospects: A Closer Look Cardano, a stalwart in the blockchain space, continues to hold its ground with its research-driven development strategy. The latest price predictions for ADA suggest potential gains, predicting a double or even quadruple increase in its valuation. Despite these optimistic forecasts, the allure of exponential gains drives traders toward more speculative ventures. The Buzz Around Solana ETF The potential introduction of a Solana ETF has the crypto community abuzz, potentially catapulting SOL prices to new heights. As investors await regulatory decisions, the impact of such an ETF on Solana's value could be substantial, potentially reaching up to $300. However, as with Cardano, the substantial market capitalization of Solana may temper its growth potential. Why Layer Brett is Gaining Traction Amidst established names, a new contender, Layer Brett, has started to capture the market's attention with its early presale stages. Offering a low entry price of just $0.0058 and promising over 700% in staking rewards, Layer Brett presents a tempting proposition for those looking to maximize returns. Comparative Analysis: ADA, SOL, and $LBRETT While both ADA and SOL offer stable investment choices with reliable growth, Layer Brett emerges as a high-risk, high-reward option that could potentially offer significantly higher returns due to its nascent market position and aggressive economic model. Initial presale pricing lets investors get in on the ground floor. Staking rewards currently exceed 690%, a persuasive incentive for early adopters. Backed by Ethereum's Layer 2 for enhanced transaction speed and reduced costs. A community-focused $1 million giveaway to further drive engagement and investor interest. Predicted by some analysts to offer up to 50x returns in coming years. Shifting Sands: Investor Movements As the crypto market landscape shifts, many investors, including those traditionally holding ADA and SOL, are beginning to diversify their portfolios by turning to high-potential opportunities like Layer Brett. The combination of strategic presale pricing and significant staking rewards is creating a momentum of its own. Act Fast: Time-Sensitive Opportunities As September progresses, opportunities to capitalize on these low entry points and high yield offerings from Layer Brett are likely to diminish. With increasing attention and funds being directed towards this new asset, the window to act is closing quickly. Invest in Layer Brett now to secure your position before the next price hike and staking rewards reduction. For more information, visit the Layer Brett website, join their Telegram group, or follow them on X by clicking the following links: Website Telegram X Disclaimer: This is a sponsored press release and is for informational purposes only. It does not reflect the views of Bitzo, nor is it intended to be used as legal, tax, investment, or financial advice.
Share
Coinstats2025/09/18 18:39
United Kingdom Trade Balance; non-EU declined to £-11.457B in November from previous £-10.255B

United Kingdom Trade Balance; non-EU declined to £-11.457B in November from previous £-10.255B

The post United Kingdom Trade Balance; non-EU declined to £-11.457B in November from previous £-10.255B appeared on BitcoinEthereumNews.com. Gold loses ground after
Share
BitcoinEthereumNews2026/01/15 16:23